DEVELOPMENT PRODUCTIVITY;
PHARMACEUTICAL-INDUSTRY;
LESSONS;
TARGETS;
CHALLENGE;
MEDICINES;
ATTRITION;
CANCER;
RATES;
D O I:
10.1126/scitranslmed.aaf2608
中图分类号:
Q2 [细胞生物学];
学科分类号:
071009 ;
090102 ;
摘要:
Our modern health care system demands therapeutic interventions that improve the lives of patients. Unfortunately, decreased productivity in therapeutics research and development (R&D) has driven drug costs up while delivering insufficient value to patients. Here, I discuss a model of translational medicine that connects four components of the early R&D pipeline-causal human biology, therapeutic modality, biomarkers of target modulation, and proof-of-concept clinical trials. Whereas the individual components of this model are not new, technological advances and a disciplined approach to integrating all four areas offer hope for improving R&D productivity.
机构:
ES Dent Coll & Hosp, Pharmacol, New Delhi, IndiaES Dent Coll & Hosp, Pharmacol, New Delhi, India
Kumar, Sahil
Roy, Vandana
论文数: 0引用数: 0
h-index: 0
机构:
Maulana Azad Med Coll, Pharmacol, New Delhi, India
Maulana Azad Med Coll, Dept Pharmacol, New Delhi 110002, IndiaES Dent Coll & Hosp, Pharmacol, New Delhi, India
机构:
Korea Finance Corp, Res Dept, 22 Eunhaeng Ro, Seoul, South KoreaKorea Finance Corp, Res Dept, 22 Eunhaeng Ro, Seoul, South Korea
Earm, Keehyun
Earm, Yung E.
论文数: 0引用数: 0
h-index: 0
机构:
Seoul Natl Univ, Coll Med, Dept Physiol, Seoul, South Korea
Keimyung Univ, Sch Med, Dept Physiol, Daegu, South KoreaKorea Finance Corp, Res Dept, 22 Eunhaeng Ro, Seoul, South Korea